Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026.
On December 30, Barclays raised its price target on Johnson & Johnson (NYSE:JNJ) to $217 from $197 and kept an Equal Weight rating on the shares. The firm reviewed sales and prescription data through the final week of December and sees room for upside to Q4 consensus estimates. The strength is coming mainly from Darzalex, Tremfya, and Simponi. Based on that trend, Barclays lifted its estimates ahead of the earnings release.
Johnson & Johnson (NYSE: JNJ) continues to generate strong free cash flow, even as it spends heavily on research and development. R&D investment reached $10.4 billion through the third quarter, putting the company among the largest investors in innovation globally. That cash flow also gives it flexibility on the deal side. Recently, the company closed its $3.1 billion acquisition of Halda Therapeutics, which brings a new platform aimed at advancing cancer treatment. Management expects these investments to support steady revenue and earnings growth, reinforcing the company’s ability to keep raising its dividend, which currently yields about 2.5%.
Oncology remains a core strength. Johnson & Johnson is one of the largest players in the space, with key products such as Rybrevant, an intravenous infusion, and Lazcluze, a once-daily pill. Used together, they target advanced non-small cell lung cancer with specific EGFR mutations. Inlexzo, developed for bladder cancer, is also expected to add momentum to the oncology portfolio.
Johnson & Johnson (NYSE:JNJ) and its subsidiaries focus on the research, development, manufacturing, and sale of a wide range of healthcare products across global markets.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Income Stocks to Buy Now and 20 Best Performing Dividend Stocks in 2025
Disclosure: None.
